Obagi Medical, a subsidiary of Waldencast (WALD), introduces its latest breakthrough: Retinol + PHA Refining Night Cream. This advanced formulation is engineered to optimize skin renewal by leveraging the efficacy of Entrapped Retinol with the scientifically proven gentle exfoliating properties of Polyhydroxy Acid Gluconolactone. This combination enhances cell turnover while reinforcing the skin barrier, resulting in a visibly refined, smoother, and more even complexion.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WALD:
- Elf Beauty, Helen of Troy exposed to China tariffs, says Canaccord
- Waldencast’s Earnings Call Highlights Growth and Innovation
- Waldencast price target lowered to $3.40 from $4.30 at TD Cowen
- Waldencast Acquisition: Hold Rating Amid Near-Term Challenges and Long-Term Potential
- Waldencast price target lowered to $5 from $6 at Telsey Advisory